RECRUITINGOBSERVATIONAL

Mechanisms And Prognosis of Stroke-Heart Syndrome

About This Trial

The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients admitted within 48 hours of onset, confirmed by CT/MRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke). 2. Moderate-to-severe stroke with NIHSS ≥ 5. Who Should NOT Join This Trial: 1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury, etc.). 2. Brain dysfunction caused by other major neurological disorders than stroke (such as brain tumors, epilepsy, Parkinson's disease, etc.). 3. Transient ischemic attack (TIA) and subarachnoid hemorrhage (SAH). 4. History of cardiac diseases (such as coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms). 5. Concomitant systemic diseases such as renal failure (eGFR \< 30), autoimmune disorders, severe infections, etc. 6. History of dementia, depression, or other psychiatric disorders. 7. Poor compliance and inability to cooperate with follow-up. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Patients admitted within 48 hours of onset, confirmed by CT/MRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke). 2. Moderate-to-severe stroke with NIHSS ≥ 5. Exclusion Criteria: 1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury, etc.). 2. Brain dysfunction caused by other major neurological disorders than stroke (such as brain tumors, epilepsy, Parkinson's disease, etc.). 3. Transient ischemic attack (TIA) and subarachnoid hemorrhage (SAH). 4. History of cardiac diseases (such as coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms). 5. Concomitant systemic diseases such as renal failure (eGFR \< 30), autoimmune disorders, severe infections, etc. 6. History of dementia, depression, or other psychiatric disorders. 7. Poor compliance and inability to cooperate with follow-up.

Locations (1)

Department of Neurology, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology

Wuhan, Hubei, China